AP2015008441A0 - Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors - Google Patents

Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors

Info

Publication number
AP2015008441A0
AP2015008441A0 AP2015008441A AP2015008441A AP2015008441A0 AP 2015008441 A0 AP2015008441 A0 AP 2015008441A0 AP 2015008441 A AP2015008441 A AP 2015008441A AP 2015008441 A AP2015008441 A AP 2015008441A AP 2015008441 A0 AP2015008441 A0 AP 2015008441A0
Authority
AP
ARIPO
Prior art keywords
pyrimido
diones
quinoline
nonsense mutation
mutation suppressors
Prior art date
Application number
AP2015008441A
Other languages
English (en)
Inventor
Carsten Spanka
Niko Schmiedeberg
Juergen Reinhardt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2015008441(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AP2015008441A0 publication Critical patent/AP2015008441A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Inorganic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2015008441A 2012-12-13 2013-12-12 Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors AP2015008441A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736748P 2012-12-13 2012-12-13
PCT/IB2013/060859 WO2014091446A1 (fr) 2012-12-13 2013-12-12 Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones utilisés en tant que suppresseurs de mutation non-sens

Publications (1)

Publication Number Publication Date
AP2015008441A0 true AP2015008441A0 (en) 2015-05-31

Family

ID=50030361

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008441A AP2015008441A0 (en) 2012-12-13 2013-12-12 Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors

Country Status (24)

Country Link
US (2) US9649314B2 (fr)
EP (1) EP2931282B1 (fr)
JP (1) JP6076498B2 (fr)
KR (1) KR101760586B1 (fr)
CN (2) CN104837490B (fr)
AP (1) AP2015008441A0 (fr)
AU (1) AU2013358591B2 (fr)
BR (1) BR112015013535A2 (fr)
CA (1) CA2890692A1 (fr)
CL (1) CL2015001610A1 (fr)
CR (1) CR20150314A (fr)
CU (1) CU20150061A7 (fr)
EA (1) EA028673B1 (fr)
ES (1) ES2709034T3 (fr)
HK (1) HK1209637A1 (fr)
IL (1) IL239244A0 (fr)
IN (1) IN2015DN03998A (fr)
MA (1) MA38157A1 (fr)
MX (1) MX363437B (fr)
PE (1) PE20151062A1 (fr)
PH (1) PH12015501216A1 (fr)
SG (1) SG11201503684WA (fr)
TN (1) TN2015000262A1 (fr)
WO (1) WO2014091446A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX363437B (es) 2012-12-13 2019-03-22 Novartis Ag Pirimido-4,5-b]-quinolina-4,5 (3h,10h)-dionas como supresoras de mutacion sin sentido.
EP3152207B1 (fr) 2014-06-03 2019-05-08 Novartis AG Dérivés de pyridopyrimidinedione comme suppresseur de mutations non-sens
PE20170086A1 (es) * 2014-06-03 2017-03-17 Novartis Ag Derivados de naftiridinadiona
ES2743184T3 (es) * 2014-06-03 2020-02-18 Novartis Ag Derivados de pirimido[4,5-b]quinolin-4,5(3H,10H)-diona como supresores de mutaciones finalizadoras
US10960018B2 (en) * 2016-04-15 2021-03-30 The Uab Research Foundation Methods and compounds for stimulating read-through of premature termination codons
US20210040074A1 (en) * 2018-03-06 2021-02-11 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Positive allosteric modulators of dopamine 1 receptor and method of use thereof
WO2019225625A1 (fr) * 2018-05-23 2019-11-28 京都薬品工業株式会社 Inducteur de translecture et utilisation pharmaceutique associée
EP4211171A2 (fr) 2020-09-10 2023-07-19 Precirix N.V. Fragment d'anticorps contre fap
MX2023008296A (es) 2021-01-13 2023-09-29 Monte Rosa Therapeutics Inc Compuestos de isoindolinona.
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
WO2023213801A1 (fr) 2022-05-02 2023-11-09 Precirix N.V. Pré-ciblage

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884170B2 (ja) * 1989-08-24 1999-04-19 株式会社フジモト・ブラザーズ ５−デアザフラビン系化合物を有効成分とする制癌剤
WO1996028444A1 (fr) 1995-03-15 1996-09-19 Pfizer Inc. INHIBITEURS DES TYROSINES KINASES, A BASE DE 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLINE-4(1H)-ONE
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
WO2004006906A2 (fr) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methodes de traitement de neoplasmes
CA2514733A1 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
SI3632902T1 (sl) 2003-04-11 2022-01-31 Ptc Therapeutics, Inc. Spojina 1,2,4-oksadiazol benzojske kisline in njena uporaba za supresijo nesmiselne mutacije in zdravljenje bolezni
PL2390255T3 (pl) 2006-04-03 2017-01-31 Technion Research & Development Foundation Ltd. Nowe aminoglikozydy i ich zastosowania w leczeniu zaburzeń genetycznych
US20080090845A1 (en) 2006-08-23 2008-04-17 Neurogen Corporation Haloalkyl-substituted pyrimidinone derivatives
CA2709784A1 (fr) 2007-12-21 2009-07-09 University Of Rochester Procede permettant de modifier la duree de vie d'organismes eucaryotes
EP2422817A1 (fr) 2010-07-29 2012-02-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Conjugués flavine-ligand d'acide nucléique
CN103189060A (zh) 2010-08-05 2013-07-03 里尔法律与医疗卫生第二大学 用于对无义突变介导的疾病进行治疗的化合物和含有所述化合物的药物组合物
MX363437B (es) 2012-12-13 2019-03-22 Novartis Ag Pirimido-4,5-b]-quinolina-4,5 (3h,10h)-dionas como supresoras de mutacion sin sentido.

Also Published As

Publication number Publication date
KR20150092306A (ko) 2015-08-12
CU20150061A7 (es) 2015-12-23
CL2015001610A1 (es) 2015-08-07
CN104837490A (zh) 2015-08-12
AU2013358591B2 (en) 2016-08-25
JP2016503003A (ja) 2016-02-01
PH12015501216A1 (en) 2015-08-17
AU2013358591A1 (en) 2015-05-28
WO2014091446A1 (fr) 2014-06-19
SG11201503684WA (en) 2015-06-29
TN2015000262A1 (en) 2016-10-03
IL239244A0 (en) 2015-07-30
US20150335646A1 (en) 2015-11-26
BR112015013535A2 (pt) 2017-07-11
MA38157A1 (fr) 2016-12-30
US9649314B2 (en) 2017-05-16
CR20150314A (es) 2015-08-10
MX363437B (es) 2019-03-22
EA201591105A1 (ru) 2015-10-30
US20170266189A1 (en) 2017-09-21
CN104837490B (zh) 2017-10-03
ES2709034T3 (es) 2019-04-12
IN2015DN03998A (fr) 2015-10-02
EP2931282B1 (fr) 2018-10-31
CA2890692A1 (fr) 2014-06-19
EP2931282A1 (fr) 2015-10-21
MX2015007562A (es) 2015-10-14
PE20151062A1 (es) 2015-08-05
JP6076498B2 (ja) 2017-02-08
KR101760586B1 (ko) 2017-07-21
EA028673B1 (ru) 2017-12-29
CN107569487A (zh) 2018-01-12
HK1209637A1 (en) 2016-04-08

Similar Documents

Publication Publication Date Title
IL239244A0 (en) Pyrimido[4,5-b] quinoline-5, 4 (3h,10h) - discussions as suppressors of non-sense mutations
HRP20181349T1 (hr) Derivat tetrahidroimidazo[1,5-d][1,4]oksazepina
HRP20171724T1 (hr) Imidazo[1,2-b]piridazin derivati kao inhibitori kinaze
HK1246792A1 (zh) 6，7-二氫吡唑並[1，5-a]吡嗪-4(5h)-酮化合物
HK1219277A1 (zh) 新的三唑並 嘧啶衍生物
HK1206014A1 (en) Pyrazolo triazine derivatives as selective cyclin dependent kinase inhinitors
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
HK1210167A1 (en) Macrocycle picolinamides as fungicides -2-
EP2945632A4 (fr) Composés [1,2,4]triazolo[1,5-c]quinazolin-5-amines à substitution hétérobicyclique ayant des propriétés d'antagonistes du récepteur a2a
EP2968311A4 (fr) Composés d'oxazolo[5,4-c]quinolin-2-one en tant qu'inhibiteurs de bromodomaines
SG11201403909RA (en) Pde9 inhibitors with imidazo triazinone backbone
HUE043108T2 (hu) (5,6-dihidro)pirimido[4,5-e]indolizinek
ZA201406323B (en) Triazolo[4,5-d]pyrimidine derivatives
HK1187614A1 (zh) 咪唑並吡嗪
EP2925876A4 (fr) Procédé de broyage
HK1206354A1 (en) Pyrrolo[2,3-b]pyrazines as syk inhibitors syk [23-b]
HK1220196A1 (zh) 抗病毒吲哚並 喹喔啉
EP2925790A4 (fr) Procédé de broyage
HK1209419A1 (en) Solid form of dihydro pyrido oxazine derivative
IL236808B (en) Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
GB201211756D0 (en) Novel isothiazolo [4,3-b]pyridines